Home › Research › Cognitive tests and assessment
Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Dubois B, López-Arrieta J, Lipschitz S, Doskas T, Spiru L, Moroz S, Venger O, Vermersch P et al.. Alzheimer's research & therapy, 2023-02-28
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia). Study AB09004 evaluated masitinib as an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate dementia due to probable Alzheimer's disease (AD). Methods Study AB09004 was a randomized, double-blind, two parallel-group (four-arm), placebo-controlled trial.
What this study adds
Evidence grade: High
This is a trial of 182 participants. This phase 3 trial tested masitinib, an oral drug targeting immune cells in the brain, as an add-on to existing dementia medications in people with mild-to-moderate Alzheimer's disease. Reported effect size: 2.5%; 97.5%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Dubois, B., López-Arrieta, J., Lipschitz, S., Doskas, T., Spiru, L., Moroz, S., et al. (2023). Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial. Alzheimer's research & therapy. https://doi.org/10.1186/s13195-023-01169-x
Vancouver
Dubois B, López-Arrieta J, Lipschitz S, Doskas T, Spiru L, Moroz S, et al. Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial. Alzheimer's research & therapy. 2023. doi:10.1186/s13195-023-01169-x. PMID: 36849969.
BibTeX
@article{dubois2023-36849969,
author = {Dubois, B. and López-Arrieta, J. and Lipschitz, S. and Doskas, T. and Spiru, L. and Moroz, S. and Venger, O. and Vermersch, P. and others},
title = {{Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial}},
journal = {Alzheimer's research \& therapy},
year = {2023},
doi = {10.1186/s13195-023-01169-x},
pmid = {36849969},
url = {https://doi.org/10.1186/s13195-023-01169-x}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Study AB09004 evaluated masitinib as an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate dementia due to probable Alzheimer's disease (AD).
- Methods Study AB09004 was a randomized, double-blind, two parallel-group (four-arm), placebo-controlled trial.
- Patients aged ≥50 years, with clinical diagnosis of mild-to-moderate probable AD and a Mini-Mental State Examination (MMSE) score of 12-25 were randomized (1:1) to receive masitinib 4.5 mg/kg/day (administered orally as two intakes) or placebo.
- A second, independent parallel group (distinct for statistical analysis and control arm), randomized patients (2:1) to masitinib at an initial dose of 4.5 mg/kg/day for 12 weeks that was then titrated to 6.0 mg/kg/day, or equivalent placebo.
Why it matters
This phase 3 trial tested masitinib, an oral drug targeting immune cells in the brain, as an add-on to existing dementia medications in people with mild-to-moderate Alzheimer's disease. It was a randomized, placebo-controlled study, so its results are needed to judge whether this drug affects the disease course.
Study details
- Participants182
- Effect size2.5%; 97.5%
- Evidence strengthHigh
How this study scored 76/100
Published in a peer-reviewed journal, and it is a large phase 3 trial. We have no data on senior author's track record, so that was left out: it earned 73 of the 96 points we could judge it on, which is 76 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer's research & therapy) |
| Journal's citation record | 1 / 4 | Alzheimer s Research & Therapy: journal h-index 146 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A large phase 3 trial (from PubMed type “Clinical Trial, Phase III”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 182 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 5 / 7 | Cited 106 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 21.2 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 4 / 6 | Cited 15.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 4 other studies in this library |
| Still being cited | 3 / 4 | Cited 96 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 2 / 3 | Inserm: institution h-index 1,988 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 15 institution(s) in 4 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36849969) |
| Free to read | 2 / 2 | Free to read |
| Points | 73 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 73 of the 96 points we could judge it on is 76 out of 100. |
| Total | 76 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13195-023-01169-x
- PubMed: 36849969
- Original source →
- Free full text: Alzheimer s Research & Therapy →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 17.
Later studies that cite this one
4 studies in the alzhub library list this one in their references.
Related studies in Cognitive tests and assessment from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.